{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T15:31:06Z","timestamp":1787671866336,"version":"build-2736575974"},"reference-count":15,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Taiwanese Journal of Obstetrics and Gynecology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.tjog.2025.01.016","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T15:00:46Z","timestamp":1787670046000},"page":"926-931","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Olaparib as the first-line maintenance therapy in advanced-stage epithelial ovarian cancer patients with BRCA mutations \u2013 Real-world experience from Taiwan"],"prefix":"10.1016","volume":"65","author":[{"given":"Wei-Jiun","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Han","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Bin","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Chun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You-Chen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung-Hsueh","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.tjog.2025.01.016_bib1","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41571-024-00881-3","article-title":"Global epidemiology of epithelial ovarian cancer","volume":"21","author":"Webb","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.tjog.2025.01.016_bib2","series-title":"Cancer registry annual report, 2024 Taiwan. Executive Yuan","year":"2025"},{"issue":"9","key":"10.1016\/j.tjog.2025.01.016_bib3","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1200\/JCO.2008.19.1684","article-title":"Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup","volume":"27","author":"Bookman","year":"2009","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1016\/j.tjog.2025.01.016_bib4","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.tjog.2025.01.016_bib5","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.molcel.2015.10.040","article-title":"Targeting the DNA damage response in cancer","volume":"60","author":"O'Connor","year":"2015","journal-title":"Mol Cell"},{"issue":"51","key":"10.1016\/j.tjog.2025.01.016_bib6","doi-asserted-by":"crossref","first-page":"85529","DOI":"10.18632\/oncotarget.13456","article-title":"Prevalence and clinical significance of BRCA1\/2 germline and somatic mutations in Taiwanese patients with ovarian cancer","volume":"7","author":"Chao","year":"2016","journal-title":"Oncotarget"},{"issue":"7","key":"10.1016\/j.tjog.2025.01.016_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2025.101645","article-title":"Prevalence of homologous recombination deficiency among women with newly diagnosed ovarian, primary peritoneal, and\/or fallopian tube cancer: the international HALO study","volume":"35","author":"Khokhlova","year":"2025","journal-title":"Int J Gynecol Cancer"},{"issue":"11","key":"10.1016\/j.tjog.2025.01.016_bib8","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1111\/jog.14090","article-title":"BRCA mutation frequency and clinical features of ovarian cancer patients: a report from a Chinese study group","volume":"45","author":"Bu","year":"2019","journal-title":"J Obstet Gynaecol Res"},{"issue":"26","key":"10.1016\/j.tjog.2025.01.016_bib9","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.tjog.2025.01.016_bib10","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.annonc.2023.07.011","article-title":"Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Gonzalez-Martin","year":"2023","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.tjog.2025.01.016_bib11","doi-asserted-by":"crossref","first-page":"512","DOI":"10.6004\/jnccn.2024.0052","article-title":"NCCN guidelines\u00ae insights: Ovarian Cancer\/Fallopian tube Cancer\/primary peritoneal cancer, version 3.2024","volume":"22","author":"Liu","year":"2024","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.tjog.2025.01.016_bib12","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ygyno.2025.01.013","article-title":"Real-world efficacy and toxicity of olaparib maintenance therapy in Korean ovarian cancer patients with an exploratory analysis of BRCA mutations","volume":"194","author":"Kim","year":"2025","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.tjog.2025.01.016_bib13","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.tjog.2021.05.010","article-title":"Olaparib asmaintenance therapy and salvage therapy in recurrent ovarian cancer: the early experience in Taiwan","volume":"60","author":"Hsu","year":"2021","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2025.01.016_bib14","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ejogrb.2024.12.021","article-title":"Haematological toxicity of PARP inhibitors in advanced ovarian cancer: a systematic review and meta-analysis","volume":"305","author":"Pio Maiorano","year":"2025","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"25","key":"10.1016\/j.tjog.2025.01.016_bib15","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus bevacizumab as first-line maintenance in ovarian cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N Engl J Med"}],"container-title":["Taiwanese Journal of Obstetrics and Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1028455926002184?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1028455926002184?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T15:01:55Z","timestamp":1787670115000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1028455926002184"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1028455926002184"],"URL":"https:\/\/doi.org\/10.1016\/j.tjog.2025.01.016","relation":{},"ISSN":["1028-4559"],"issn-type":[{"value":"1028-4559","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Olaparib as the first-line maintenance therapy in advanced-stage epithelial ovarian cancer patients with BRCA mutations \u2013 Real-world experience from Taiwan","name":"articletitle","label":"Article Title"},{"value":"Taiwanese Journal of Obstetrics and Gynecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tjog.2025.01.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Taiwan Association of Obstetrics & Gynecology. Publishing services by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}